Background: Significant analytic variability exists between the multiple assays for cardiac troponin I (cTnI) approved for clinical use. Until adequate cTnI standardization is possible, an evidence-based approach evaluating each assay at specific thresholds appears warranted. Methods: We examined the efficacy of three cTnI assays for predicting death, myocardial infarction (MI), or the composite of death, MI, or urgent revascularization at 43 days among patients with non-ST-elevation acute coronary syndromes enrolled in the Thrombolysis In Myocardial Infarction (TIMI) 11B study. Results: Six hundred eighty-one patients with serum samples obtained at baseline and/or 12-24 h had cTnI determined using all three assays. Baseline cTnI was >0.1 g/L for 368, 395, and 418 patients with the Bayer Immuno 1 TM , ACS:180 ® , and Dimension ® RxL assays, respectively. Correlation coefficients for the RxL with the ACS:180 and Bayer Immuno 1 results were 0.89 (P ‫؍‬ 0.0001) and 0.87 (P ‫؍‬ 0.0001), with a coefficient of 0.92 (P ‫؍‬ 0.0001) for the ACS:180 and Bayer Immuno 1 assays. Patients with cTnI >0.1 g/L were at increased risk for death or MI by 43 days (relative risk, 2.2-3.0; P  <0.0006) , regardless of the assay used. This prognostic capacity persisted among those with creatine kinase MB isoenzyme concentrations within the reference interval. Moreover, cTnI was the strongest multivariate predictor of death, MI, or urgent revascularization with adjusted odds ratios of 2.1-2.9 (P <0.0006). Conclusion: This study demonstrates the prognostic efficacy of three independently developed cTnI assays at a threshold of 0.1 g/L for the prediction of adverse clinical outcomes among patients with non-ST-elevation acute coronary syndromes.
The cardiac-specific troponins are highly sensitive and specific markers of myocardial necrosis (1) (2) (3) (4) (5) , as well as effective tools in the prognostic assessment of patients with unstable ischemic heart disease. The performance of cardiac troponin T as a risk marker in acute coronary syndromes is well characterized at a threshold of 0.1 g/L (ng/mL) using a single commercially available assay (6 -8 ) . Whereas increased cardiac troponin I (cTnI) 4 has likewise been shown to correlate with adverse outcomes in unstable angina and non-Q-wave myocardial infarction (NQMI), (9 -14 ) , there are several barriers to similar standardization of cTnI for application in this setting (8 ) .
Multiple assays for cTnI have been approved by the Food and Drug Administration for clinical use and are available commercially. Furthermore, conformational changes in cTnI as it circulates as free, binary, or ternary complexes with troponins C and T (8, 15 ) , and differences in the susceptibility of specific protein epitopes to degradation (8, 16 ) may variably alter the immunoreactivity of sites targeted by different immunoassay systems. Given that the impact of these factors is heterogeneous across individual assays, reported results for the same sample may vary up to 20-fold between the different analytical methods (8 ) . This phenomenon is reflected in the diversity of decision limits used in clinical studies, as well as diagnostic thresholds offered by manufacturers.
This variability in decision limits may be a source of confusion for clinicians reviewing the clinical literature or moving between institutions that use different assays. However, until analytic methods for cTnI determination are better standardized, specific thresholds established for individual assays should not be generalized, and the clinical efficacy of each cTnI assay at a given decision limit should be established in well-conducted clinical studies (17 ) . To provide a guide for clinical use, we thus sought to evaluate the performance of three commercially available cTnI assays for risk assessment in a cohort of patients with non-ST-elevation acute coronary syndromes participating in a contemporary clinical trial.
In its "Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers" (18 ) , the National Academy of Clinical Biochemistry (NACB) has stated that detection of any myocardial injury with a specific cardiac marker such as cTnI is clinically important and warrants the incorporation of a low abnormal decision limit for the optimum use of such markers in acute coronary syndromes. The NACB expert committee has further recommended that this lower decision limit for cardiac troponin assays be guided by the 97.5th percentile among healthy controls or the minimum detectable concentration (MDC) when all healthy individuals tested have cTnI concentrations below the detection limit (18 ) . We previously demonstrated the adverse prognosis associated with increases in cTnI above 0.4 g/L (MDC for the Stratus ® II assay, Dade Behring) among patients with non-ST-elevation acute coronary syndromes in the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical trial (9 ) . Application of a more recent generation of this assay (RxL Dimension ® troponin I; Dade Behring) in a similar cohort of patients from TIMI 11B has shown that cTnI is a robust predictor of poor early clinical outcomes at a threshold of 0.1 g/L (19 ) . We now extend our analysis of this population with a simultaneous evaluation of the analytic and prognostic performance of three current generation cTnI assays at a decision limit equal to the 97.5th percentile for healthy controls or MDC (cTnI Ն0.1 g/L) with respect to 43-day outcomes among patients with unstable angina and NQMI enrolled in TIMI 11B.
Materials and Methods patients
The TIMI 11B trial design, and inclusion and exclusion criteria have been published previously (20 ) . Men and women enrolled at any of the 111 North or South American centers participating in TIMI 11B were eligible for this substudy. TIMI 11B was a randomized, double-blind, parallel group trial of the low-molecular weight heparin, enoxaparin, compared with unfractionated heparin for the treatment of patients presenting with unstable angina or NQMI. Participants in TIMI 11B were required to have an episode of ischemic discomfort at rest occurring within 24 h of enrollment. In addition, patients were required have evidence of ischemic heart disease, including ST depression on the qualifying electrocardiogram (ECG) or an increased serum cardiac marker [creatine kinase (CK) more than two times the upper limit of normal (ULN); CK MB isoenzyme (CKMB) above the ULN] (20 ) . Exclusion criteria included evidence of an evolving Q-wave myocardial infarction (MI), plans for revascularization regardless of response to medical therapy in the first 24 h, coronary artery bypass grafting in prior 2 months or percutaneous transluminal angioplasty in prior 6 months, and renal insufficiency [serum creatinine Ͼ20 mg/L (2.0 mg/dL)]. The TIMI 11B protocol, including the biomarker substudy, was approved by the institutional review board at each enrolling site, and written informed consent was obtained from patients before study entry.
blood sampling and measurement of serum markers
The serum marker protocol specified that upon enrollment and 12-24 h later venous blood samples be drawn and serum stored at Ϫ20°C or colder at the enrolling site until shipped to the Core Laboratory at Children's Hospital Medical Center (Boston, MA) where samples were then stored at Ϫ80°C. Samples were thawed and separated into several aliquots. cTnI was measured using the Dimension RxL cTnI assay (21 ) dimension RxL cTnI assay
The cTnI (TROP) method for the Dimension RxL system is a colorimetric one-step sandwich immunoassay. The dayto-day precision of this assay in our laboratory (Brigham and Women's Hospital) at cTnI concentrations of 0.57, 2.58, and 12.22 g/L was reflected by CVs of 8.8%, 3.1%, and 1.5%, respectively. At a concentration of 0.1 g/L, the SD was 0.027 g/L, and the MDC was 0.04 g/L. The 97.5th percentile for 197 healthy blood donors tested in our laboratory was 0.1 g/L. A threshold of 1.5 g/L is suggested by the manufacturer as consistent with acute myocardial infarction (AMI).
acs:180 cTnI assay
The ACS:180 assay for cTnI is an automated system utilizing a two-site sandwich immunoassay and direct chemiluminometric technology. The day-to-day precision of this assay in the Core Laboratory at cTnI concentrations of 1.1, 16.1, and 34.1 g/L was reflected by CVs of 8.3%, 9.4%, and 8.7%, respectively. Data from the manufacturer show a CV of 13% at 0.1 g/L. The MDC was determined as 2 SD above the mean signal for 37 replicate measurements of the zero calibrator in the Core laboratory and was 0.1 g/L. A diagnostic cutoff for AMI of 1.5 g/L is suggested by the manufacturer. The 97.5th percentile among 158 healthy controls was given as Ͻ0.1 g/L in data provided to us by the manufacturer.
bayer immuno 1 cTnI assay
The Bayer Immuno 1 system assay for cTnI is a heterogeneous sandwich magnetic separation assay utilizing mouse monoclonal anti-cTnI and goat polyclonal antitroponin I antibodies. The day-to-day reproducibility of this assay in the Core Laboratory at cTnI concentrations of 0.2, 1.7, 7.1, and 49.9 g/L was reflected by CVs of 11%, 4.9%, 2.8%, and 2.8%, respectively. The MDC was 0.1 g/L. cTnI concentrations Ն0.9 g/L with this assay have been observed by the manufacturer to be indicative of AMI. The 97.5th percentile among 158 healthy controls was below the MDC for this assay in data provided to us by the manufacturer.
clinical definitions
The diagnosis of the presenting ischemic syndrome for patients enrolled in TIMI 11B was made by the site investigator on the basis of WHO criteria for AMI, using serial measurements of CK/CKMB as defined in the TIMI 11B protocol (20 ) and collected on the Initial Hospitalization Case Report Form. A MI was considered to be present at enrollment if any of the following criteria were met: (a) CKMB above the ULN and Ն3% of total CK in samples obtained at baseline or ϳ8 h after enrollment; (b) CKMB was increased in the 16-h sample, and no ischemic discomfort Ͼ30 min had occurred between study entry and the 16-h sample; (c) total CK more than two times the ULN (if CKMB measurements unavailable); (d) ECGs obtained at 8 or 16 h after enrollment revealed new Q waves (Ͼ0.03 s) in two or more contiguous leads (20 ) . Patients presenting with an ischemic syndrome without AMI by these criteria were diagnosed with unstable angina. The definition of the clinical endpoint of MI for TIMI 11B was restricted to new AMI occurring after the qualifying ischemic event and required either new diagnostic Q waves or left bundle branch block not present on the enrollment ECG or criteria for enzyme evidence of new infarction (20 ) . An increase of CKMB to above the ULN and at least 50% over the prior value, or (if CKMB unavailable) re-elevation of total CK more than two times the ULN and Ն25% of the previous value were sufficient to meet enzymatic criteria for new AMI. For subjects within 24 h of coronary angioplasty or surgical coronary bypass grafting, total CK or CKMB were required to be Ն50% of the prior value as well as three and five times the 
Results baseline characteristics
This substudy of TIMI 11B included 681 patients with serum samples obtained at baseline and/or 12-24 h after enrollment available for determination of cTnI using all three cTnI assays. There were 637 patients with baseline samples available for cTnI measurement, 546 patients with both baseline and 12-24 h samples, and 44 patients with the late sample only. Demographic characteristics of the cTnI substudy population were representative of those for the overall trial (Table 1 ) with a profile indicative of severe unstable ischemic heart disease, and notable for ST-segment deviation on Ͼ70% of presenting ECGs. Patients with increased cTnI (any of the three assays) were more likely to be male and to have ECG abnormalities, especially ST depression (0.5 mm or more), at presentation. They were less likely to report a history of prior angina.
cTnI results
In this high-risk population of patients with unstable angina or NQMI, baseline cTnI values were abnormal (Ն0.1 g/L) for 368 (58%), 395 (62%), and 418 (66%) of Values Ͼ60 g/L were excluded for each assay to facilitate comparison in the predominant operating range. SE Est., standard error of the estimate. patients with the Bayer Immuno 1, ACS:180, and Dimension RxL assays, respectively. Among those patients with unstable angina and available baseline samples (n ϭ 322), the number of individuals with increased baseline cTnI with the Bayer Immuno 1, ACS:180, and Dimension RxL assays were 102 (32%), 119 (37%), and 148 (46%), respectively.
Strong positive correlation was evident between cTnI results from each of the three assays. Spearman correlation coefficients for the Dimension RxL with the ACS:180 and Bayer Immuno 1 assay baseline measurements were 0.89 (P ϭ 0.0001) and 0.87 (P ϭ 0.0001), respectively, with a correlation coefficient of 0.92 (P ϭ 0.0001) for the ACS:180 and Bayer Immuno 1 cTnI results. Regression lines for these relationships are shown in Fig. 1 . Agreement between categorical (positive/negative) baseline cTnI results was good to excellent (25 ) for the Dimension RxL and Bayer Immuno 1 ( ϭ 0.66), Dimension RxL and ACS:180 ( ϭ 0.73), and the ACS:180 and Bayer Immuno 1 ( ϭ 0.78) assays.
clinical outcomes
Among the 681 patients with cTnI measurements, there were 30 deaths (4.4%) by 43 days. Fifty-three patients (7.8%) suffered a MI after the qualifying index event, and 86 (12.6%) had recurrent ischemia requiring urgent revascularization by 43 days. Final diagnoses for the presenting symptoms made by the site investigators on the basis of WHO criteria using CK/CKMB results were unstable angina for 50.7% and NQMI for 42.4%, with Ͻ7% of participants being diagnosed with Q-wave MI or noncardiac chest pain.
Individuals with an increased cTnI as determined with each of the three assays were at significantly increased risk for adverse clinical events by 43 days, including a two-to threefold higher risk of suffering death or MI ( Table 2 ). Similar risk relationships were evident when only the baseline samples were used for prognostic assessment (Fig. 2) . Furthermore, among the subgroup of patients with unstable angina, increased cTnI was a potent predictor of adverse outcomes including death, MI, and the composite primary endpoint of death, MI, or urgent revascularization by 43 days (Fig. 3) .
In a regression model including clinical risk factors (age, gender, history of coronary artery disease, diabetes, hypertension, and smoking status) as well as ST-segment depression on the qualifying ECG and evidence of congestive heart failure on admission, the prognostic capacity of baseline values of cTnI persisted after adjustment for these clinical variables (Table 3) . Moreover, regardless of the assay used, baseline cTnI was the strongest prognostic indicator even after controlling for other recognized predictors of cardiovascular risk (adjusted odds ratios of 2.2-2.9; P Ͻ0.0006).
Of those individuals who suffered an adverse clinical event (death, MI, or urgent revascularization), baseline categorical results (positive/negative) differed between the ACS:180 and Dimension RxL for 13 (9.8%), of whom 10 had positive results with the Dimension RxL and negative with the ACS:180 (P ϭ 0.05, McNemar's test). Similarly, there were discordant results between the Dimension RxL and Bayer Immuno 1 assays for 16 patients, 15 of whom had positive results with the Dimension RxL (P ϭ 0.001, McNemar's test).
Discussion
Our study of patients presenting with non-ST-elevation acute coronary syndromes demonstrates the prognostic efficacy of three independently developed assays for cTnI. Specifically, we show that cTnI concentrations Ն0.1 g/L (97.5th percentile of healthy controls or MDC) as determined with each of these assays are predictive of higher risk for adverse clinical outcomes by 43 days, including death, MI, or recurrent ischemia prompting urgent revascularization. Moreover, we found that the robust prognostic capacity of these three cTnI assays persists after adjustment for multiple important clinical risk indicators, including ST-segment deviation. This prognostic utility is evident for each of these commercially available assays in spite of analytic variability characterized in this report.
The targeting of different protein epitopes by the unique anti-cTnI antibody components of each of the available cTnI immunoassay systems is responsible for much of the variation in the signal detected by these assays (26 ) . Notably, disparity in the signal is influenced not only by diversity of the epitopes recognized but also by interaction between the locations of these protein regions and the actions of proteolytic enzymes causing degradation at both the COOH and NH 2 termini of cTnI (26, 27 ) . In addition, conformational changes resulting from the association of cTnI with troponins C and T in binary and ternary complexes may have differing effects on the accessibility of individual epitopes (8 ) . As such, the establishment of a reference material based on a single cTnI complex type, (e.g., binary cTnIC), may allow calibration of individual assays with respect to a primary standard but will not eradicate all of the variation between assays that incorporate different antibodies (8, 28 ) .
Although clinicians and clinical chemists must be cognizant of the intermethod variability and the current lack of standardization for cTnI assays, these factors do not obviate the clinical utility of cTnI as a prognostic marker, as evident in this report of data from TIMI 11B. However, one must be cautious about generalization of thresholds established for a specific assay. Until adequate cTnI standardization is possible, an evidence-based approach requiring investigation of individual thresholds for each available assay appears warranted (17 ) .
Several large clinical studies have demonstrated the utility of cTnI for risk stratification in various settings. Among patients with non-ST-elevation acute coronary syndromes enrolled in TIMI III, increased cTnI (Ն0.4 g/L) was associated with increased mortality at 6 weeks after presentation (9 ) . In addition, the GUSTO-IIa Investigators observed that among 770 individuals with acute coronary syndromes that included ST-elevation MI, cTnI concentrations Ն1.5 g/L (Stratus II; Dade Behring) at enrollment identified those at higher risk for death by 30 days (7 ) . Furthermore, the TRIM investigators demonstrated that cTnI concentrations Ն2.0 g/L (Opus; Behring Diagnostics) were associated with higher 30-day mortality among 516 patients with unstable angina (11 ) . Now the increased sensitivity of current generation cTnI assays has enabled the evaluation of new lower decision limits for risk stratification. In our current study, we demonstrated the clinical efficacy of the Dimension RxL, ACS:180, and Bayer Immuno 1 cTnI assays at a decision threshold of 0.1 g/L (97.5th percentile of healthy controls or MDC for each of the assays evaluated) for risk assessment among patients presenting with non-ST-elevation acute coronary syndromes.
study limitations
The preferred method for determining the optimal prognostic threshold for clinical use of the cardiac troponins has been a subject of some debate. However, the current standard offered by the NACB Standards of Laboratory Practice as a Class I recommendation is that the low abnormal decision limit be "established for each marker on a population of healthy individuals, using the 97.5th percentile (one tail) of results" (18 ) . Thus, we used this standard embraced by the NACB Expert Committee on the Use of Cardiac Markers in Coronary Artery Diseases in defining the predetermined decision limits for this substudy. Although the utility of ROC curves for selection of clinically optimal prognostic cut-points is not universally accepted, we retrospectively constructed ROC curves for each of the troponin assays ( Fig. 4) , lending additional support for the thresholds used in this study. Although cTnI concentrations above the MDC or 97.5th percentile were predictive of adverse clinical outcomes with each of the assays evaluated in this study, differences in analytic and clinical performance were detected and underscore the difficulties in generalizing clinical cutpoints in the absence of adequate standardization for cTnI assay methods. It bears emphasizing that the prognostic decision limits utilized for each assay were selected independently and that although they converged on a common result, these data should not be extrapolated to other assays not evaluated in the clinical setting. Furthermore, this study was designed as a concurrent prognostic evaluation of three assays in current clinical use rather than as a direct method comparison and thus may be extrapolated to the latter only with limitations because testing conditions between methods were subject to minor variations. For example, as noted in Materials and Methods, the aliquots used for the ACS:180 and Bayer Immuno 1 cTnI determinations had undergone one additional freezethaw (Ϫ80°C) cycle. Although data from the manufacturers demonstrating the stability of cTnI measurements with the ACS:180 and Bayer Immuno 1 assays across multiple freeze-thaw cycles (B. Bluestein, Bayer Diagnostics, Tarrytown, NY, personal communication) render it unlikely that this factor contributed significantly to vari-ation between these and the Dimension RxL assay, we cannot exclude an impact. However, even allowing for this possibility, cTnI as determined with each of these assays was a strong predictor of outcomes.
Finally, one must maintain some caution in extrapolating our data using a low abnormal prognostic decision limit among patients with a high-risk clinical profile and unstable ischemic heart disease to a more heterogeneous population of patients presenting with chest pain syndromes. However, it is interesting to note that using a point-of-care device (Spectral Diagnostics) with a similar low range detection limit of 0.1 g/L, Hamm et al. (29 ) found that a positive cTnI among patients presenting to an emergency department with chest pain was associated with higher risk for cardiac death or nonfatal MI over a follow-up of 30 days.
In conclusion, cTnI is a highly specific and sensitive marker of myocardial necrosis with documented utility for risk assessment in unstable coronary disease. Analytic variability between multiple available assays requires that specific decision limits proposed for clinical use be evaluated for each assay in well-conducted clinical studies. Our report responds to this mandate, demonstrating the clinical efficacy of three current generation commercially available cTnI assays at a threshold of 0.1 g/L for risk stratification in non-ST-elevation acute coronary syndromes.
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